FIELD: pharmaceuticals.
SUBSTANCE: invention relates to an acylated derivative of GLP-1(7-37), intended for preventing and/or treating diabetes. Proposed are an analogue of the polypeptide GLP-1(7-37), a fatty acid-modified derivative of said analogue, and a medicinal product containing said derivative. Also proposed is a method for producing said derivative and an application thereof for producing a medicinal product.
EFFECT: production of an acylated derivative of GLP-1 suitable for preventing and/or treating diabetes.
14 cl, 6 dwg, 9 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT AND LUBRICANT | 2019 |
|
RU2807183C2 |
| MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
| LONG-ACTING DOUBLE AGONIST OF GLUCAGON-LIKE PEPTIDE-1 AND GLUCAGON RECEPTORS | 2021 |
|
RU2799327C1 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
| ACYLATED GLP-1 COMPOUNDS | 2006 |
|
RU2434019C2 |
| NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES | 2021 |
|
RU2822001C1 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
